amphastar
pharmaceuticals
reports
financial
results
three
months
ended
september
rancho
cucamonga
globe
newswire
amphastar
pharmaceuticals
nasdaq
amph
amphastar
company
today
reported
results
three
months
ended
september
third
quarter
highlights
net
revenues
million
third
quarter
gaap
net
income
million
per
share
third
quarter
adjusted
net
income
million
per
share
third
quarter
jack
zhang
amphastar
president
chief
executive
officer
commented
demonstrated
growth
due
continued
strength
primatene
epinephrine
vial
product
additionally
excited
significant
progress
intranasal
epinephrine
product
product
illustrates
scientific
technical
three
months
ended
nine
months
ended
september
september
thousands
except
per
share
data
net
revenues
gaap
net
income
attributable
amphastar
adjusted
net
income
attributable
amphastar
gaap
diluted
eps
attributable
amphastar
stockholders
adjusted
diluted
eps
attributable
amphastar
stockholders
adjusted
net
income
attributable
amphastar
adjusted
diluted
eps
attributable
amphastar
stockholders
financial
measures
please
see
discussion
section
entitled
financial
measures
reconciliation
gaap
financial
measures
table
iii
press
release
third
quarter
results
three
months
ended
september
change
dollars
thousands
net
revenues
primatene
enoxaparin
lidocaine
phytonadione
naloxone
epinephrine
finished
pharmaceutical
products
total
finished
pharmaceutical
products
net
revenues
api
total
net
revenues
changes
net
revenues
primarily
driven
increased
sales
primatene
mist
primarily
resulting
continued
success
nationwide
television
radio
digital
marketing
campaign
growth
online
sales
amazon
launching
primatene
mist
kroger
largest
grocery
store
chain
united
states
primarily
resulting
continued
success
nationwide
television
radio
digital
marketing
campaign
growth
online
sales
amazon
launching
primatene
mist
kroger
largest
grocery
store
chain
united
states
increased
sales
enoxaparin
primarily
due
higher
unit
volumes
increased
epinephrine
sales
due
launch
recently
approved
epinephrine
injection
usp
vial
product
second
quarter
decreased
naloxone
sales
due
lower
average
selling
price
increased
competition
decreased
lidocaine
finished
pharmaceutical
product
sales
due
lower
demand
largely
due
competitors
returning
normal
distribution
levels
three
months
ended
september
change
dollars
thousands
net
revenues
cost
revenues
gross
profit
net
revenues
changes
cost
revenues
resulting
gross
margin
primarily
driven
increased
sales
primatene
mist
launch
epinephrine
injection
vial
higher
margins
launch
epinephrine
injection
vial
higher
margins
decreased
sales
naloxone
finished
pharmaceutical
products
higher
margins
three
months
ended
september
change
dollars
thousands
selling
distribution
marketing
general
administrative
research
development
marketing
distribution
expenses
increased
primarily
related
primatene
mist
including
cost
national
television
radio
digital
marketing
campaign
began
july
including
cost
national
television
radio
digital
marketing
campaign
began
july
general
administrative
expenses
increased
primarily
due
increased
legal
expenses
research
development
expenses
decreased
due
lower
expenses
china
partially
offset
increased
domestic
expenses
related
generic
inhalation
product
pipeline
insulin
biosimilar
programs
intranasal
epinephrine
program
cash
flow
provided
operating
activities
nine
months
ended
september
million
impact
result
pandemic
first
quarter
second
quarter
sales
primatene
certain
hospital
products
increased
sales
certain
products
frequently
used
elective
produces
lidocaine
jelly
decreased
third
quarter
sales
products
returned
levels
closer
experienced
prior
pandemic
company
experienced
significant
negative
impacts
cash
flows
operations
result
pandemic
company
production
facilities
continued
operate
quarter
prior
pandemic
little
change
enhanced
safety
measures
intended
prevent
spread
virus
possible
time
estimate
complete
impact
pandemic
could
business
including
customers
suppliers
impact
depend
future
developments
pandemic
highly
uncertain
predicted
pipeline
information
company
currently
five
andas
file
fda
targeting
products
market
size
approximately
billion
three
biosimilar
products
development
targeting
products
market
size
approximately
billion
nine
generic
products
development
targeting
products
market
size
approximately
billion
market
information
based
iqvia
data
months
ended
september
company
currently
developing
multiple
proprietary
products
injectable
intranasal
dosage
forms
amphastar
chinese
subsidiary
anp
currently
drug
master
files
dmfs
file
fda
developing
several
additional
dmfs
company
information
amphastar
specialty
pharmaceutical
company
focuses
primarily
developing
manufacturing
marketing
selling
generic
proprietary
injectable
inhalation
intranasal
products
additionally
company
sells
insulin
api
products
company
finished
products
used
hospital
urgent
care
clinical
settings
primarily
contracted
distributed
group
purchasing
organizations
drug
wholesalers
information
resources
available
amphastar
logo
trademarks
service
marks
amphastar
including
limited
primatene
property
amphastar
financial
measures
supplement
consolidated
financial
statements
prepared
presented
accordance
generally
accepted
accounting
principles
gaap
company
disclosing
financial
measures
providing
financial
results
company
believes
evaluation
ongoing
operations
comparisons
current
operations
historical
future
operations
would
difficult
disclosure
financial
results
limited
financial
measures
prepared
accordance
gaap
result
company
disclosing
certain
results
including
adjusted
net
income
loss
attributed
amphastar
ii
adjusted
diluted
eps
attributed
amphastar
stockholders
exclude
amortization
expense
compensation
impairment
charges
executive
severance
expense
legal
settlements
order
supplement
investors
readers
understanding
assessment
company
financial
performance
company
management
uses
measures
internally
forecasting
budgeting
measuring
operating
performance
whenever
company
uses
measures
provide
reconciliation
financial
measures
directly
comparable
gaap
financial
measures
investors
readers
encouraged
review
related
gaap
financial
measures
reconciliation
measures
directly
comparable
gaap
measures
set
forth
consider
measures
supplement
substitute
superior
measure
measures
financial
performance
prepared
accordance
gaap
conference
call
information
company
hold
conference
call
discuss
financial
results
today
november
pacific
time
access
conference
call
dial
international
callers
five
minutes
conference
passcode
conference
call
call
also
accessed
investors
page
company
website
statements
statements
press
release
conference
call
referenced
historical
statements
including
among
things
statements
relating
company
expectations
regarding
future
financial
performance
backlog
sales
marketing
products
market
size
growth
product
development
timing
fda
filings
approvals
including
dmfs
anp
timing
product
launches
acquisitions
matters
related
pipeline
product
candidates
share
buyback
program
future
events
impact
pandemic
related
responses
business
governments
pandemic
operations
personnel
commercial
activity
demand
across
business
operations
results
operations
statements
historical
facts
rather
based
amphastar
historical
performance
current
expectations
estimates
projections
regarding
amphastar
business
operations
similar
related
factors
words
may
might
could
would
anticipate
predict
potential
continue
expect
intend
plan
project
believe
estimate
similar
related
expressions
used
identify
statements
although
statements
contain
words
place
undue
reliance
statements
involve
known
unknown
risks
uncertainties
assumptions
difficult
impossible
predict
cases
beyond
amphastar
control
actual
results
may
differ
materially
statements
result
number
factors
including
described
amphastar
filings
securities
exchange
commission
including
annual
report
form
year
ended
december
filed
sec
march
particular
extent
impact
business
depend
several
factors
including
severity
duration
extent
pandemic
well
actions
taken
governments
businesses
consumers
response
pandemic
continue
evolve
remain
uncertain
time
locate
reports
company
website
http
sec
website
statements
release
speak
date
release
amphastar
undertakes
obligation
revise
update
information
statements
press
release
conference
call
referenced
reflect
events
circumstances
future
even
new
information
becomes
available
subsequent
events
cause
amphastar
expectations
change
contact
information
amphastar
pharmaceuticals
bill
peters
chief
financial
officer
table
amphastar
pharmaceuticals
condensed
consolidated
statement
operations
unaudited
thousands
except
per
share
data
three
months
ended
nine
months
ended
september
september
net
revenues
cost
revenues
gross
profit
operating
expenses
selling
distribution
marketing
general
administrative
research
development
total
operating
expenses
income
operations
income
expenses
net
income
income
taxes
income
tax
provision
net
income
net
income
loss
attributable
interests
net
income
attributable
amphastar
net
income
per
share
attributable
amphastar
stockholders
basic
diluted
shares
used
compute
net
income
per
share
attributable
amphastar
stockholders
basic
diluted
table
ii
amphastar
pharmaceuticals
condensed
consolidated
balance
sheets
unaudited
thousands
except
share
data
september
december
unaudited
assets
current
assets
cash
cash
equivalents
restricted
cash
investments
restricted
investments
accounts
receivable
net
inventories
income
tax
refunds
deposits
prepaid
expenses
assets
total
current
assets
property
plant
equipment
net
finance
lease
assets
operating
lease
assets
goodwill
intangible
assets
net
assets
deferred
tax
assets
total
assets
liabilities
stockholders
equity
current
liabilities
accounts
payable
accrued
liabilities
income
taxes
payable
current
portion
debt
current
portion
operating
lease
liabilities
total
current
liabilities
reserve
income
tax
liabilities
debt
net
current
portion
operating
lease
liabilities
net
current
portion
deferred
tax
liabilities
liabilities
total
liabilities
commitments
contingencies
stockholders
equity
preferred
stock
par
value
shares
authorized
shares
issued
outstanding
common
stock
par
value
shares
authorized
shares
issued
outstanding
september
shares
issued
outstanding
december
respectively
additional
capital
retained
earnings
accumulated
comprehensive
loss
treasury
stock
total
amphastar
pharmaceuticals
stockholders
equity
interests
total
equity
total
liabilities
stockholders
equity
table
iii
amphastar
pharmaceuticals
reconciliation
measures
unaudited
thousands
except
per
share
data
three
months
ended
nine
months
ended
september
september
gaap
net
income
adjusted
intangible
amortization
compensation
impairment
assets
expense
related
executive
separation
agreement
gain
litigation
settlement
income
tax
benefit
provision
adjustments
net
income
net
income
loss
attributable
interests
net
income
attributable
amphastar
net
income
per
share
attributable
amphastar
stockholders
basic
diluted
shares
used
compute
net
income
per
share
attributable
amphastar
stockholders
basic
diluted
three
months
ended
september
selling
general
research
income
cost
distribution
income
tax
provision
interest
revenue
marketing
administrative
development
expense
net
benefit
adjustment
gaap
intangible
amortization
compensation
impairment
assets
income
tax
provision
benefit
adjustments
reconciliation
measures
continued
three
months
ended
september
selling
general
research
income
cost
distribution
income
tax
provision
interest
revenue
marketing
administrative
development
expense
net
benefit
adjustment
gaap
intangible
amortization
compensation
impairment
assets
income
tax
provision
benefit
adjustments
nine
months
ended
september
selling
general
research
income
cost
distribution
income
tax
provision
interest
revenue
marketing
administrative
development
expense
net
benefit
adjustment
gaap
intangible
amortization
compensation
impairment
assets
expense
related
executive
separation
agreement
income
tax
provision
benefit
adjustments
